Apellis Pharma has become the first company to claim FDA approval for a drug to treat geographic atrophy (GA), a sight-robbing condition that accompanies age-related macular degeneration (AMD ...

where the FDA gave Syfovre the go-ahead for GA secondary to AMD in February 2023, the first drug to be approved for the condition. Apellis said it hopes to get a verdict from the latest appeal in ...

Apellis stock toppled Tuesday after third-quarter sales of the company's eye drug, Syfovre, widely missed Wall Street's expectations.Please watch the video at Investors.com - How To Buy Stocks: Ways ...

Apellis Pharmaceuticals APLS announced that ... secondary to age-related macular degeneration (AMD). Shares of the company ...

Nov. 05, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals ... U.S. net product revenue in the third quarter 2024. SYFOVRE commercial vials grew by approximately 7% quarter-over-quarter.

When it comes to desktop and laptop processors, the two biggest names in town are Intel and AMD. Qualcomm is making inroads, but if you want peak performance, Intel and AMD make the best ...

AMD has launched its third generation commercial AI mobile processors designed specifically to transform business productivity with Copilot+ features including live captioning and language translation ...

If you're planning to upgrade your rig, now is the ideal time to look for the best AMD processor for your needs and budget. With Black Friday deals approaching, you can find some fantastic deals ...

with commercial shipments expected in the first half of 2025. One of the understated elements of AMD’s AI strategy is seen in an image above: the acquisition of Silo AI. This Finnish company ...

Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.